Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Savara ( (SVRA) ).
In January 2026, Savara updated its corporate presentation to provide an expanded overview of autoimmune pulmonary alveolar proteinosis (autoimmune PAP), the burden of disease, and the limitations of existing care such as whole lung lavage, an invasive and non‑standardized procedure that does not address the underlying pathophysiology and often must be repeated. The materials underscore significant unmet medical need, including high morbidity, increased healthcare utilization, risk of serious infections, and substantial impact on patients’ daily lives, thereby reinforcing the strategic rationale for Savara’s development of MOLBREEVI and signaling the company’s continued positioning as a specialist player in rare respiratory diseases, with potential implications for future regulatory, clinical, and commercial milestones.
The most recent analyst rating on (SVRA) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Savara stock, see the SVRA Stock Forecast page.
Spark’s Take on SVRA Stock
According to Spark, TipRanks’ AI Analyst, SVRA is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and heavy cash burn alongside declining equity). Technicals provide partial support due to a clear uptrend and positive momentum, while valuation offers limited support given negative earnings and no dividend data.
To see Spark’s full report on SVRA stock, click here.
More about Savara
Savara Inc. is a biopharmaceutical company focused on developing new therapies for rare respiratory diseases, with its lead investigational product MOLBREEVI (molgramostim inhalation solution) in development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a chronic, life‑threatening lung disorder for which there are currently no approved drug treatments in the U.S. or Europe. The company highlights a seasoned executive leadership team spanning clinical, commercial, regulatory, and technical operations to support the advancement and potential commercialization of therapies targeting this underserved patient population.
Average Trading Volume: 2,602,194
Technical Sentiment Signal: Buy
Current Market Cap: $1.17B
See more data about SVRA stock on TipRanks’ Stock Analysis page.